Sanofi | Jotup

JDRF Walk to Cure Diabetes

Retrieved on:

金曜日, 5月 31, 2024

Partnership, Sanofi, Diabetes, Walking, Parent, JDRF, Risk, Paratriathlon, Education, Diagnosis, Disease, Autoimmune disease, Death, Research, Insulin, Medicine, Amputation, Family, Pharmaceutical industry

TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The JDRF Walk to Cure Diabetes is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research.

Key Points:

TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The JDRF Walk to Cure Diabetes is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research.
Funds raised from the JDRF Walk to Cure Diabetes will help improve lives of Canadians living with T1D by accelerating life-changing breakthroughs to treat, prevent and cure T1D.”
The Walk’s newest sponsor, Sanofi, has come onboard as National Awareness Partner.
“We're proud to sponsor the JDRF Walk to Cure Diabetes to provide an opportunity for people across Canada to come together and raise awareness about type 1 diabetes, ensuring that education and support are available to all."
“As part of this commitment, Abbott is honoured to continue our partnership with JDRF in supporting families and accelerating research and innovation in treating type 1 diabetes.”
Learn more about the 2024 JDRF Walk to Cure Diabetes and help us move T1D research forward faster: jdrfwalk.ca

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Retrieved on:

金曜日, 5月 31, 2024

Sanofi, Patient, Food, FDA, Safety, Regeneron Pharmaceuticals, EMA, COPD, Chronic obstructive pulmonary disease, Committee, European, CHMP, Pharmaceutical industry

The FDA did not raise any concerns regarding the approvability of Dupixent for this indication.

Key Points:

The FDA did not raise any concerns regarding the approvability of Dupixent for this indication.
The FDA had requested additional efficacy analyses on the efficacy of Dupixent in the BOREAS and NOTUS pivotal trials.
Sanofi and Regeneron are confident that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA to bring Dupixent to patients living with uncontrolled COPD as quickly as possible.
Additionally, submissions for Dupixent in COPD are currently under review with regulatory authorities around the world, including the European Union and China.

SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth

Retrieved on:

木曜日, 5月 30, 2024

Sanofi, Patient, Business, Doctor of Pharmacy, GSK, Marketing, Growth, Culture, AstraZeneca, Vertex

Philadelphia, PA, May 30, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective 3 June 2024.

Key Points:

Philadelphia, PA, May 30, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective 3 June 2024.
Ms. Wolfeler brings more than 20 years of experience in the global healthcare and biotechnology industries, and deep expertise in strategy, commercial operations, business development and leading global teams.
Prior to that, Ms. Wolfeler held senior roles at Vertex, Shire, Baxalta, AstraZeneca, and GSK, across US, UK and France.
Jeremie Urbain, Chairman of SERB Pharmaceuticals, said: “Vanessa is an accomplished leader with broad management experience, a track record of commercial successes, and expertise in scaling up organisations.

OSE Immunotherapeutics Provides Business and Corporate Update

Retrieved on:

木曜日, 5月 30, 2024

NANTES, France, May 30, 2024 – 6:15pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided business and corporate update after reinforcement of the Company’s business-model based on strategic pharmaceutical partnerships following the three recent new agreements concluded with AbbVie and Boehringer Ingelheim.

Key Points:

NANTES, France, May 30, 2024 – 6:15pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided business and corporate update after reinforcement of the Company’s business-model based on strategic pharmaceutical partnerships following the three recent new agreements concluded with AbbVie and Boehringer Ingelheim.
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “We achieved major industrial partnerships from our differentiated immunological pipeline and our sustainable innovation engine.
On February 28th, OSE Immunotherapeutics and AbbVie announced partnership to develop OSE-230, a novel monoclonal antibody for the treatment of chronic inflammation.
On May 24th, OSE Immunotherapeutics and Boehringer Ingelheim expanded their collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases.

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

Retrieved on:

火曜日, 5月 28, 2024

From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics.

Key Points:

From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics.
Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.
Mr. Bienaimé currently serves on the board of directors of Incyte Corporation and Immunome, Inc., as well as serving on the board of directors of a private biotechnology company.
Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

TransPerfect Announces GlobalLink NEXT Americas 2024 Conference in New York

Retrieved on:

火曜日, 5月 21, 2024

Sanofi, Learning, Western Digital, HPE, Citizens Bank, AI, University of Cambridge, Trek Bicycle Corporation, Verity Harding, TransPerfect, AWS, Language

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- TransPerfect , the world’s largest provider of language and AI solutions for global business, today announced its ninth annual GlobalLink NEXT Americas conference will be held June 25–26, 2024, at the Sheraton Times Square in New York City.

Key Points:

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- TransPerfect , the world’s largest provider of language and AI solutions for global business, today announced its ninth annual GlobalLink NEXT Americas conference will be held June 25–26, 2024, at the Sheraton Times Square in New York City.
TransPerfect’s annual AI and technology user event features learning and networking opportunities, bringing together GlobalLink users, industry professionals, and technology experts.
Curated around this year’s theme of “Intelligence Everywhere,” the event will feature GlobalLink product spotlights, client case studies, and breakout tracks.
“With the theme of ‘Intelligence Everywhere,’ GlobalLink NEXT 2024 will feature our largest-ever focus on AI and how these new solutions can be game changers for organizations operating internationally,” said Matt Hauser, Chief Experience Officer at TransPerfect.

Nurix Therapeutics Announces Board Chair Transition

Retrieved on:

月曜日, 5月 20, 2024

Sanofi, Patient, Lexicon Pharmaceuticals, Infection, Chair, Read, University, Therapy, SAN, Compensated emancipation, Inflammation, Cancer, Audit committee, Growth, Drug discovery, George Washington University, Punk, Corporate development, Pharmaceutical industry

SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L. Lacey, M.D., stepped down as board chair at the conclusion of today’s annual meeting of stockholders. The board of directors has unanimously elected board member Julia P. Gregory as its new board chair.

Key Points:

Current board member Julia P. Gregory unanimously elected new board chair
SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L. Lacey, M.D., stepped down as board chair at the conclusion of today’s annual meeting of stockholders.
The board of directors has unanimously elected board member Julia P. Gregory as its new board chair.
Dr. Lacey, who has served on the Nurix board since 2016, and as board chair since 2019, will remain on the board and will continue to serve as chair of its Compensation Committee and as a member of its Development Advisory Committee.
“David has been an outstanding board chair and on behalf of the board, I thank him for his leadership.

Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting

Retrieved on:

月曜日, 5月 20, 2024

Partnership, Sanofi, Heart, NVAX, Shareholder, Marketing, Vaccine, AI, Research, Human, Pharmaceutical industry

RALEIGH, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Shah Capital Management, Inc. (together with its affiliates, “Shah Capital,” “we” or “our”) collectively beneficially owns ~7.9% of the outstanding common stock of Novavax, Inc. (NASDAQ: NVAX) (“Novavax” or the “Company”), making it a top three and largest non-index stockholder, today issued the below statement to stockholders regarding its intended efforts at the 2024 Annual Meeting of Stockholders scheduled for Thursday, June 13, 2024, 8:30 a.m. Eastern Time (the “2024 Annual Meeting”):

Key Points:

It is unfortunate, however, that it took our campaign to galvanize the Board into action.
However, we do accept that decent progress has now at last been made and that is why we have determined to withdraw our proxy campaign against the re-election of directors at Novavax’s 2024 Annual Meeting.
We thank thousands of fellow shareholders who supported Shah Capital in our campaign and who shared our concerns about the direction of the Company.
Together, we have helped to deliver real change at Novavax.

Boston Pharmaceuticals Announces Former NIH Director, Dr. Elias Zerhouni, As the New Chair of Its Board of Directors

Retrieved on:

木曜日, 5月 23, 2024

Biotechnology, Pharmaceutical, Health, Sanofi, Bangladesh Technical Education Board, Executive Committee, MASH, Chair, Hepatology, Biomedical engineering, Biomedicine, Medication, Johns Hopkins University, OPKO Health, FGF21, Pharmaceutical industry

Dr. Zerhouni has been a Board member and Scientific Advisor at Boston Pharmaceuticals since 2021.

Key Points:

Dr. Zerhouni has been a Board member and Scientific Advisor at Boston Pharmaceuticals since 2021.
In assuming the position of Chair, he will now work even more closely with Sophie Kornowski, CEO of Boston Pharmaceuticals, her team, and the community of liver experts as the company’s promising drug candidates accelerate their development.
I also want to thank Stefan for all of his many and sizeable contributions and accomplishments during his time as a colleague.
He is, since 2020, a member of the Board at B-Flexion and is also President and Vice Chairman of OPKO Health .

Innate Pharma: Clarification Regarding SAR443579 Designation

Retrieved on:

火曜日, 5月 21, 2024

Oncology, Health, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, Sanofi, IPH, Congress, IPHA, Fast track (FDA), Euronext Paris

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.

Key Points:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.
This is an error.
The molecule has US FDA Fast Track Designation, as communicated before in June 2023.